2750.T
The company operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.
Business. The company operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.
The company maintains a capital structure with a debt-to-equity ratio of 1.01, indicating a balanced mix of debt and equity financing. Its liquidity position is characterized by a current ratio of 1.41, suggesting moderate short-term liquidity. However, the company's operating cash flow is negative at -1,062,418,000 JPY, which may raise concerns about its ability to fund operations from operating activities.
In terms of profitability, the company's return on equity is 7.26%, which is a measure of how effectively it uses shareholders' equity to generate profits. The return on assets of 2.26% indicates the efficiency of asset utilization in generating earnings. These metrics should be compared against the industry's preferred metrics to assess the company's performance relative to its peers.
The company's revenue is concentrated in the Food & Drug Retailing segment, with no disclosed geographic diversification. This concentration may expose the company to specific market risks, such as regional economic downturns or changes in consumer behavior.
The company's growth trajectory is reflected in its revenue of 64,953,996,000 JPY. While the outlook for the current fiscal year is not explicitly provided, the company's capital expenditure of -1,146,196,000 JPY suggests ongoing investment in its operations. The absence of a detailed outlook for the next fiscal year makes it difficult to assess the company's future growth potential.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations. The dilution risk is low, suggesting that the company is not expected to issue additional shares that could dilute existing shareholders' equity.
Recent events, such as the latest actual EPS of 114.50 JPY and revenue of 64,954,000,000 JPY, provide insight into the company's recent performance. These figures are in line with the company's financial snapshot and indicate a stable earnings and revenue generation.
- The company has a balanced capital structure with a debt-to-equity ratio of 1.01.
- The company's return on equity is 7.26%, indicating a moderate level of profitability.
- The company's liquidity position is moderate, with a current ratio of 1.41.
- The company's operating cash flow is negative, which may impact its ability to fund operations from operating activities.
- The company's revenue is concentrated in the Food & Drug Retailing segment, with no disclosed geographic diversification.
- **margin_outlook_rationale**: The company's gross profit margin is expected to remain stable, driven by consistent pricing and cost management strategies.
- **rd_outlook_rationale**: Research and development expenditures are not disclosed, but the company's focus on retail operations suggests minimal R&D investment.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 2750.T Market data — financials · 2026-05-26
- S.Ishimitsu & Co Ltd Market data — analyst estimates · 2026-05-26